Q-omics provides the consensus-scored LANCL3 profile across patient tissues and cancer cell-line models. LANCL3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LANCL3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LANCL3 RNA expression shows 15,043 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where LANCL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LANCL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LANCL3 survival associations across molecular data types. LANCL3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LANCL3 RNA expression–survival associations across cancer types. High LANCL3 expression shows unfavorable associations in UVM, MESO, STAD and SCLC, but favorable associations in ACC and LUSC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LANCL3 RNA expression.
This table summarizes LANCL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LANCL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LANCL3 shows lower tumor expression in KIRC, COAD, KIRP, LUAD, BRCA and READ. The KIRC box plot shows higher LANCL3 RNA expression in normal versus tumor tissue (log2 FC = −0.322, t-test p < 0.001).
This table shows molecular features associated with LANCL3 in patient tissues and cancer cell lines. In patient samples, LANCL3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LANCL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
